CRISPR Therapeutics AG

CRSP: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
V&wLOCK|^@LOCK|?j#<XMM

Crispr Earnings: Promising Phase 1 Data for CTX310; Casgevy Launch Gaining Traction

Crispr Therapeutics made progress in the third quarter on its commercialization efforts for gene therapy Casgevy and early-stage pipeline candidates, notably CTX310 for high triglycerides and LDL cholesterol. It posted a net loss of $106 million and $1.9 billion in cash and marketable securities.

Sponsor Center